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Abstract 
Diabetes is one of the leading causes of death in the United States and can cause severe impairments to 
those diagnosed. Prediabetes is a state when a patient has higher fasting plasma glucose levels than a 
non-diabetic person but is not quite high enough to be considered diabetes. Both diabetic and 
prediabetic patients are at higher risk for cardiovascular diseases (CVD), which is the leading cause of 
death in the United States. The primary form for prevention and treatment of CVD is through statin 
therapy. Statins are a class of medications used to treat and prevent CVD by limiting cholesterol 
production in the liver and stabilizing plaque in arteries. However, substantial research has found an 
association between statin use and the development of Type 2 diabetes. This is an important association 
to investigate because both statin use and diabetes are prevalent in the United States. 
The association between statin use and the development of Type 2 diabetes poses a complicated risk for 
prediabetic patients. Because they are already at high risk for diabetes, taking a statin could further 
increase this risk. However, preventing CVD, which they are also at risk for, is critical as well. This 
research investigates the relationship between statin use and prediabetic subjects specifically.  
An adult, prediabetic subpopulation was obtained from the National Health and Nutrition Examination 
Survey (NHANES), which is made publicly available through the Center for Disease Control and 
Prevention. Several random forest classifiers were built using this subpopulation to predict statin use 
among prediabetic patients. Analysis of the models found age, cholesterol levels, blood pressure levels, 
waist size, body mass index (BMI), and annual household income to be the best predictors of statin use 
in prediabetic subjects. Access to health insurance, gender, family history of heart attacks, and overall 
health rating were found to be the least impactful predictors of statin use among prediabetic subjects in 
all models. It appears the risk of CVD outweighs the risk of developing Type 2 diabetes, and doctors are 
continuing to prescribe statins for prediabetic patients despite the increased risk of developing diabetes. 
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1. Introduction 
1.1 Background 
Diabetes is the seventh-leading cause of death in the United States and affects over 30 million 
Americans [1]. Type 1 diabetes occurs when the body does not make enough insulin and accounts for 
5% of cases of diabetes [2]. This form of diabetes cannot be prevented. Type 2 diabetes is much more 
common and is when the body cannot use insulin properly. Insulin is a hormone made by the pancreas 
used to regulate blood sugar levels, which can lead to health complications if not properly controlled [3]. 
People who have diabetes can suffer from complications such as blindness, kidney failure, heart disease, 
stroke, and loss of extremities [4].  
Prediabetes is a state of latent impairment of carbohydrate metabolism in which the criteria for 
diabetes are not all satisfied [5]. According to the American Diabetes Association (ADA), there are 
approximately 3 million newly diagnosed prediabetes cases each year, and approximately 38% of adults 
in the U.S. have prediabetes  [6] . Most patients with prediabetes have impaired fasting glucose, 
impaired glucose tolerance, metabolic syndrome, and high cholesterol levels. These conditions, along 
with lifestyle choices, cause prediabetic patients to have a high risk of cardiovascular disease, similar to 
patients with type 2 diabetes [7]. It is recommended pharmacological treatment be started to prevent 
progression into type 2 diabetes. 
Prediabetic and diabetic patients are at high risk for cardiovascular disease (CVD). CVD, which is 
disease of the heart including diseased vessels, structural problems, and blood clots, is the leading cause 
of death in the United States [8]. The primary form for prevention and treatment of CVD is through 
statin therapy. Statins, one of the most widely prescribed types of medication in the United States, are a 
class of medications used to prevent CVD by limiting cholesterol production in the liver and stabilizing 
plaque in arteries [9]. Figure 1 shows the progression of cholesterol buildup progressively worsening 
from left to right. The image on the right of the figure shows a blood clot, which can be deadly. Statins 
can save lives by preventing this buildup. 
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Figure 1. Healthy blood flow (left) progressing to a blood clot (right) as cholesterol builds up in arteries.  
 
 Unfortunately, substantial research has linked statin use with the development of Type 2 
diabetes [10]. Figure 2 shows a clear difference between statin users (red) and non-statin users (blue) in 
the percent of Type 2 diabetes instances in the respective populations. The study concluded being a 
statin user was significantly associated with an increased risk of new onset diabetes [11]. Many other 
research studies have reached the same conclusion. This is an important association to investigate 
because both diabetes and statin use are so prevalent in the United States. 
 
 
Figure 2. Comparison of percent of incident diabetes between statin users and non-users. [11] 
 
 The association between statin use and the development of Type 2 diabetes poses a 
complicated risk for prediabetic patients. Because they are already at high risk for diabetes, taking a 
statin could further increase this risk. However, preventing CVD, which they are also at risk for, is critical 
as well. There are some cases where taking a statin might be worth it, and others where it may not.  
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1.2 Literature Review 
For years researchers have been investigating the association between statin use and new-onset 
diabetes mellitus (NODM), which is when a subject with no previous history of diabetes develops and is 
diagnosed with diabetes. A robust 2010 meta-analysis of over 90,000 subjects found statin therapy is 
correlated with NODM, especially in older subjects [12]. This analysis also found the longer a subject had 
been on statins, the more likely he or she was to develop NODM [12]. This study did not look at a 
prediabetic population specifically.  
 A 2012 study examined statin risk along with cardiovascular outcomes in the general population. 
The study found rates of diabetes were significantly higher in statin users (p < .001) over a median of 7.2 
years [13]. However, major adverse cardiovascular events (MACE) and in-hospital mortality related to 
cardiovascular events were less [13]. Through risk-benefit analysis, it was determined that statin 
treatment was favorable in both high-risk and secondary treatment subjects in the general population 
[13]. Secondary treatment is defined as “screening to identify diseases in the earliest stages, before the 
onset of signs and symptoms, through measures such as mammography and regular blood pressure 
testing” [14]. 
 A post-hoc analysis of a clinical trial found subjects with one or more risk factors for diabetes 
were at higher risk for NODM when subject to statin therapy than those with no major risk factors [15]. 
However, in individuals with one or more risk factors for diabetes, more adverse cardiovascular events 
and deaths were avoided than new-onset cases of diabetes [15]. This suggests prediabetic subjects may 
be at even higher risk for developing NODM than non-diabetic subjects. However, this risk may be worth 
it considering the reduction in adverse cardiovascular events.  
 In 2012, the U.S. Food and Drug Administration updated their guidelines to add a safety warning 
to statins indicating an increased risk for development of diabetes [16]. This change supports much of 
the research done in this area; however, little research has been done to analyze prediabetic subjects 
specifically. One study that did examine prediabetic subjects specifically found statin therapy is 
associated with an increased risk in development of NODM [17]. Despite the risk of NODM, prediabetic 
subjects would benefit from taking statins due to decreased risk of MACE and morbidity associated with 
cardiovascular events [17]. 
While many studies have addressed the link between statin use and the onset of Type 2 diabetes, 
research needs to be done specifically for high-risk patients like those with prediabetes. Little previous 
research analyzes how the medical community is currently handling this dilemma. While the long-term 
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research goal is to develop a guideline on statin initiation for prediabetes patients, this research 
analyzes the current practices with respect to statin use among prediabetes patients. We predict statin 
use among a prediabetic population and analyze the resulting model to determine how this dilemma is 
currently being handled. 
 The remainder of this thesis is organized as follows: Section 2 details the methodologies used to 
reach our conclusions, including data collection and processing, data validation, and model 
development. Section 3 states the results of the model, and Section 4 explains and draws conclusions 
from these results. 
2. Methodologies 
This section summarizes research methodologies. Subsection 3.1 gives an overview of the National 
Health and Nutrition Examination Survey (NHANES) data set, publicly available through the Center for 
Disease Control and Prevention (CDC), and how specific sections of the data were selected and 
processed for this research. Subsection 3.2 describes the extensive process of selecting and validating a 
subpopulation of prediabetic patients. Subsection 3.3 details the algorithms and methods used to build 
and train the model. Subsection 3.4 describes the methods used for model testing and validation. 
2.1 Data Collection and Processing 
NHANES is a survey of noninstitutionalized civilian residents of the United States population in their 
homes with a laboratory component taking place in mobile examination centers. The questionnaire 
portion of the survey ranges from weight history to smoking habits while the laboratory examination 
tests for diseases, pregnancy, and, most importantly for this research, levels of different measures in the 
body [18]. These measures include blood sugar levels, cholesterol levels, and insulin levels [18]. 
Participants are able to opt out of the laboratory examination if they choose to do so, and, for this 
reason, there are fewer responses for the laboratory examination portion. Respondent personal 
information, such as name and address, are not disclosed, and respondents are instead identified by a 5-
digit sequence number. This sequence number allows us to link participants’ responses from different 
sections of the survey and from the laboratory examination. We have chosen to use the 2015-2016 
survey data because it was the most recent published survey at the time this research started.  
 Because NHANES does not classify or categorize respondents in any way, we had to classify 
prediabetic patients. There are various indicators commonly used by doctors to diagnose prediabetes 
and diabetes including fasting plasma glucose (FPG) levels, the oral glucose tolerance test (OGTT), and 
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hemoglobin A1C numbers. In the NHANES laboratory examination, FPG and OGTT were both taken. 
Because healthcare professionals most commonly use FPG to diagnose prediabetes and diabetes, we 
chose this test as our basis to classify respondents as “prediabetic”, “diabetic”, or “non-diabetic” [19]. 
Table 1, published by the American Diabetes Association (ADA), defines the criteria for prediabetes and 
diabetes based on FPG. 
 
Table 1. Summary table of prediabetes and diabetes classification standards [20]. 
 
 The FPG test was completed by 2,972 respondents. Of these respondents, 1,227 were classified 
as prediabetic. In the diabetes section of the survey, there is a question asking if a respondent has ever 
been told they have diabetes by a doctor. Of those who responded “yes” to this question, 91 were a part 
of the initial prediabetic subpopulation. Because these respondents had previously been diagnosed with 
diabetes and were most likely treated for it, they were taken out of the subpopulation. Their treatment 
for diabetes could be the reason they are now prediabetic by FPG level. Removing these respondents 
brought the sample size down to 1,136. Finally, respondents under the age of 18 were removed. 
Pediatric and adult diabetes are treated differently by the medical community and should be analyzed 
separately. For this reason, we chose to focus on adult population. This subpopulation of 1,029 was used 
for subsequent analysis. The process for arriving at the subpopulation is illustrated in Figure 3. 
 
Figure 3. Process for arriving at final subpopulation for analysis. 
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There is a question on the NHANES survey asking respondents if they have ever been told by a 
doctor they have prediabetes. We chose not to use the answers to this question to define our 
subpopulation because of the high number of missing responses and because patients may be 
considered prediabetic even if they have not been diagnosed by a doctor. We did, however, use the 
responses to this question for data validation, which will be discussed further in Section 3.2. The 
demographic distributions of this final population are shown in Table 2. 
Table 2. Distributions of demographics of final population. 
 
 
The response variable for the model is whether a prediabetic respondent is prescribed statins. 
This response was determined using the “Prescription Medications” survey from the questionnaire 
section. A question in this survey asked respondents to list all prescription medications they were taking 
at the time of response. If one of the medications a respondent listed was a statin, they were given a “1” 
as their response value. If they did not list a statin, they were given a “0” as their response value. There 
was a question in the “Blood Pressure and Cholesterol” section asking if a respondent is prescribed 
medicine for cholesterol, which is often a statin. The answer to this question was not used as the 
response due to (1) a higher rate of missing values and (2) the “Prescription Medication” survey would 
have been used to verify this cholesterol medication was a statin. The response to this question was 
instead used for data validation, which will be discussed further in Section 3.2. 100% of the prediabetic 
subpopulation responded to the prescription medication survey, so there was no missing response data. 
Male Female
Gender 55.00% 45.00%
18-29 30-44 45-59 60-74 75+
Age 13.90% 24.39% 25.85% 25.36% 10.50%
Other
Race/Ethnicity 3.69%
1 2 3 4 5 6 7+
Household Size 14.38% 28.38% 17.59% 15.84% 10.59% 6.71% 6.51%
<20k (20k,45k] (45k,65k] (65k,75k] (75k,100k] >100k
Annual Income 23.05% 28.07% 16.22% 5.55% 10.99% 16.12%
Education
Demographics Distributions
Mexican American
18.76%
Other Hispanic Non-Hispanic White Non-Hispanic Black Non-Hispanic Asian
13.31% 36.93% 15.26% 12.05%
Less than 9th grade 9th-11th grade High School grad/GED Some college or AA College grad or above
13.08% 12.07% 22.33% 28.37% 24.14%
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 Eighteen predictors were chosen from various surveys in the questionnaire. Table 3 outlines 
which survey each predictor is from and whether the predictor is demographic, health-related, or 
behavioral. These categories will later be used to determine which types of factors are best at predicting 
statin use. Predictors were chosen based on their potential to have a relationship with diabetes or 
cholesterol levels. Age, gender, race, education, smoking, and family history of heart problems were 
used to predict statin use in a study examining adults in the United States [21]. Predictors were also 
chosen based on the quality of the data. Many survey questions had more than 25% of responses 
missing and were therefore eliminated from consideration.  
 
 
Table 3. Categorization of predictors chosen from NHANES. 
Survey Predictor Type 
Blood Pressure & Cholesterol Has a doctor ever told you that you have high blood 
pressure? 
Has a doctor ever told you that you have high 
cholesterol? 
Health-related 
Health-related 
Body Measures BMI 
Waist size (cm) 
Health-related 
Health-related 
Consumer Behavior Money spent on carryout food (past 30 days) Behavioral 
Demographics Gender 
Age (in years) 
Household size  
Annual family income 
Education level 
Race 
Demographic 
Demographic 
Demographic 
Demographic 
Demographic 
Demographic 
Diet and Nutrition Diet health rating (self-rating) 
Number of fast food meals (past 30 days) 
Number of ready-to-eat foods (past 30 days) 
Behavioral 
Behavioral 
Behavioral 
 
General Health Health rating (self-rating) Health-related 
Health Insurance Covered by Insurance  Demographic 
Medical Conditions Close relative had a heart attack Health-related 
Smoking – Cigarette Use Smoke at least 100 cigarettes in life Health-related 
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2.2 Data Validation 
To determine which analysis techniques were the most appropriate for the data set, further 
investigations were performed. A multicollinearity study was completed because many analysis 
techniques assume independence, and if multicollinearity was present, some options would not be 
appropriate. Each predictor was compared to the other 17 predictors to determine if there was a 
significant relationship between the variables. Due to the categorical nature of the data, the Pearson 
correlation coefficient could not be used to detect relationships between variables. Instead, a Chi-
square test of independence was completed for each pair of predictors. A summary table of the results 
can be found in the appendix. Based on a level of significance of .05, about 57% of the predictor pairs 
had a significant relationship. In conclusion, the dataset exhibited strong multicollinearity. This makes 
analyses that assume independence of predictor variables, such as regression analysis, inappropriate for 
our model.  
 Most questions in the NHANES questionnaire were not completed by 100% of respondents. For 
this reason, we had to handle missing data. The question used for the response variable, asking 
respondents which prescriptions they were taking at the time of the questionnaire, was completed by all 
respondents in our subpopulation. Handling missing data is especially important for the response 
variable of a model, so it is fortunate this was the case. However, nine predictors, shown in Table 4, had 
at least one observation missing.  
 
Table 4. Predictors with at least one observation missing and their corresponding missing percentage. 
  
 Missing data was handled in three different ways: (1) treating missing as a category, (2) 
implementing a k-nearest neighbor imputation, and (3) excluding all missing observations. Because the 
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predictors are all categorical, it is appropriate to make missing its own category. This was done because 
the fact the observation was missing could hold predictive power. In one version of the dataset, all null 
values were replaced with a “-1” to indicate the variable was missing. Machine learning algorithms in 
python will not run with null values, so the null values had to be mapped to a numerical value. Negative 
one was chosen because no predictors take negative form. 
 The second approach to handling missing data was with a k-nearest neighbors (kNN) imputation. 
kNN is an algorithm that takes the 𝑘 observations most similar to the observation with a missing value 
and calculates the median or mean, depending on the type of variable, for the missing category [22]. 
This mean or median replaces the missing value. The value 𝑘 was chosen to be five because it is 
relatively low, which increases the prevalence of local effects, and odd, which prevents ties for binary 
predictors [22]. 
 The third way of handling missing data was removing any observations with one or more values 
missing in any category. To ensure this was an appropriate measure to take, we verified the data was 
missing at random (MAR) [22]. We did this by comparing the distribution of the complete dataset with 
the distribution of the missing-removed dataset for each predictor. An example is shown in Figure 5. If 
the distributions look similar, it is fair to assume the data is missing at random. This was the case for all 
18 predictors, making the missing-removed dataset valid. 
 
Figure 4. BMI distributions for a) the complete dataset and b) the missing-removed dataset 
 
 
Because the response variable is so critical, in addition to comparing the distributions, a two-
sample proportion test was completed. Because the response is binary, a proportion hypothesis test is 
ideal. At the level of significance of 0.1, no significant difference was found between the complete 
dataset and the missing-removed dataset. This also verifies the data is MAR because respondents who 
left questions blank were not more likely to be prescribed a statin. 
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2.3 Model Development 
The machine learning algorithm chosen for this model was a Random Forest Classifier (RFC). Due to the 
presence of multicollinearity, discussed in Section 2.2, a model that assumes independence would be 
inappropriate. The categorical nature of most of the predictors and binary nature of the response 
variable were also factors in the selection of appropriate machine learning methods. For example, 
because we know for certain which category the response should fall into (either taking statin or not 
taking statin), a clustering algorithm such as k-means would not be appropriate. Algorithms requiring 
very large amounts of data, such as neural networks, would also not be appropriate because the final 
subpopulation included 1,029 observations. The ideal algorithm does not assume independence of 
predictors, does not require very large data sets, and works well for classification (non-continuous) 
responses. An RFC meets these requirements and therefore was used to create the models. 
 An RFC was created for each of the three ways of handling missing data, totaling in three 
models. All categorical predictors were mapped to integer values so the Python algorithm could run 
properly, and most were on an ordinal scale. This was the first step completed with each of the three 
datasets.  
 After being prepared, the datasets were read into Python as a Pandas data frame. They were 
then separated into two arrays: one for predictors and one for the response. These arrays were split into 
a training set and a testing set. The training set contained 70% of the data, and the testing set contained 
30%. The training set is used to build and fit the model, while the testing set is used to evaluate how 
well the model is predicting. It is necessary to create both sets to properly evaluate a predictive model. 
 The RFC was built using a Random Forest Classifier method from the SciKit Learn library’s 
“Ensemble” module [23]. The random state was set to 1, and 1,500 trees were used. Increasing the 
number of trees improved prediction performance without taking too much time. Because RFCs are not 
sensitive to overfitting, it was not a problem to use 17 predictors.   
2.4 Model Testing 
The testing set was used to evaluate model performance. For each algorithm built, the F1 score, percent 
accuracy, and confusion matrix were output. An F1 score is a common metric for evaluating 
classification algorithms that considers both precision and recall [24]. A confusion matrix is a 2x2 matrix 
containing the frequencies of true positives, false positives, false negatives, and true negatives. The F1 
score and confusion matrix were computed using SciKit Learn’s “Metrics” module. The percent accuracy 
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was computed using a method in SciKit Learn’s “Ensemble” module. The results of these performance 
metrics for each model are shown in Table 5. 
Model F1 Score 
Percent 
Accuracy 
Confusion 
Matrix 
Missing as category 0.495 83% 
[[230 20] 
[33 26]] 
kNN imputation .519 83% 
 [[229  21] 
   [ 31  28]] 
Missing removed 0.51 86% 
[[135 5] 
[20 13]] 
Table 5. Model performance for each predictive model. 
 
2.5 Subsequent Modeling 
While RFCs can be great predictors, it is also common practice to use the importance information they 
output for subsequent modeling. We used this approach in the feature subsect selection process for 
further modeling. Cholesterol, blood pressure, age, waist size, and BMI were chosen to be used in 
additional models because they were consistently important features across all RFC models.  
 We wanted to continue using classification models, so we decided to use a logistic regression, 
which is a binary classification model. However, a simple logistic regression would not be sufficient on 
its own due to presence of multicollinearity in the data. For this reason, regularization techniques were 
used. Regularization techniques include penalty terms that penalize less important features so they do 
not affect the outcome of the model as much as other features [25].  
There are three common types of regularization methods: ridge, lasso, and elastic net. Ridge 
regression can penalize features to make them less important, but they will never reach zero [25]. Lasso 
regression is similar to ridge regression but can penalize features to zero and get rid of their information 
completely [25]. Elastic net regression is a hybrid between ridge and lasso. It can perform similar to lasso 
regressions but may perform better when features are highly correlated [26]. 
Features from the original dataset were all standardized to a 0 to 1 scale, and dummy variables 
were created to represent the different age categories. Missing data was handled in only one way by 
imputing the missing values. The package glmnet was then used in R to create the regularized 
regressions [27]. The equation in Figure 5 shows how the penalty term is set up in this package. When 
the parameter 𝛼 is set to 0, the lasso penalty disappears, and the model is a ridge regression. When 𝛼 is 
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set to 1, the ridge penalty disappears, and the result is a lasso regression. An 𝛼 between 0 and 1 results 
in an elastic net regression. 
 
Figure 5. Demonstration of penalty term in glmnet package. 
 
 The confusion matrices and prediction accuracies for the three methods are shown in Figure 6. 
Of the values tested, 𝛼=.5 was the best-performing elastic net regression. The elastic-net regression 
performed the best for this data, and the ridge regression performed the worst. However, all models 
performed pretty similarly.  
 
Figure 6. Confusion matrices and accuracy of predictions for each type of regularized logistic regression. 
 
 
3. Results 
An RFC is a black box machine learning algorithm, meaning it is difficult to see what is happening 
internally to cause the model to predict the way it is. For this reason, there are two ways to assess the 
effects of the predictors. There is a high-level conclusion, which shows the importance of predictors 
relative to each other. This is typically the more useful insight. There are also instance-level results, 
which show how one specific observation was affected by each predictor to reach the predicted 
response. This is not as useful because not as much insight can be gained from one specific instance. For 
this reason, we focused on the relative importance of predictors (referred to as feature importance). 
The relative importance of the first model, where missing was a category, is shown in Figure 7. 
This model predicted with 83% accuracy. Generally, statin use was underpredicted. The model predicted 
roughly 13% statin use while the real number is close to 17%. This could be due to statin use being the 
minority response.  
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Figure 7. Feature importance obtained by the RFC where missing was a category 
 
The relative importance of the second model, where missing observations were removed, is 
shown in Figure 8. This model predicted with 86% accuracy, making it more accurate than the previous 
model. This model also underpredicted statin use. While the most important features are similar to the 
previous model, they are not exactly the same. Age was a much more important feature when missing 
values are removed. High blood pressure is much less important, moving from the third most important 
feature to the eleventh. Waist size, BMI, and annual income are in similar positions. High cholesterol, as 
expected, is still a very important feature despite not being the most important in the second model. 
Whether a participant smokes changed from being one of the least important features in the previous 
model the seventh most important feature in this model.  
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Figure 8. Feature importance obtained by the RFC when observations with missing values are removed. 
 
  
 The relative feature importance of the third model, where missing values were imputed, is 
shown in Figure 9. This model predicted with 83% accuracy, making it just as accurate as the first and 
less accurate than the second. The relative feature importance order in this model was very similar to 
the first. The top three features, high cholesterol, age, and high blood pressure, were the same. Waist 
size, BMI, and annual income were also very important in the first model but in a different order. 
Gender, insurance, and family heart attack history were the least important features in all three models.  
 
Figure 9. Feature importance obtained by the RFC when missing values were imputed.  
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4. Discussion and Conclusion 
Among all three models, high cholesterol, age, BMI, waist size, annual income, and household size 
seemed to be the best predictors of statin use in prediabetic patients. High cholesterol being a very 
important feature in all models is intuitive because the U.S. Food and Drug Administration classifies 
statins as a class of drugs used to treat high cholesterol [28]. A 2006 study found a positive correlation 
between BMI and cholesterol in the general population; this could be a reason why BMI is fairly good 
predictor of statin use [29]. A 1998 study found larger households are less likely to be on a low-
cholesterol diet, perhaps contributing to why household size was a relatively important feature [30]. 
Meanwhile, gender, family history of heart attacks, and whether a patient had insurance were 
the least impactful features. Aside from these three features, however, the order of the least impactful 
predictors varied between models. We found the fact that insurance is among the least impactful 
features in all three models surprising. Having medical insurance would seem to be a factor that would 
make accessing statins easier; however, this does not appear to be the case among prediabetic patients. 
One possible explanation for this is that statins are so important to patients they will ensure they have 
the medication whether insured or not.  
 Another result we found surprising was the low ranking of smoking. A 1991 study of adults 
found that cholesterol increased in both men and women for each cigarette smoked daily [31]. The U.S. 
Food and Drug Administration describes statins as a drug used to lower cholesterol [28]. Because 
smoking can raise cholesterol and statins can lower it, it would seem natural for them to have a 
relationship; however, that does not appear to be the case in these models.  
In Table 3 in Section 2.1, the features of the model were categorized as “Demographic,” 
“Behavioral,” or “Health-related.” In general, health-related features such as blood pressure, 
cholesterol, BMI, and waist size were of the highest importance. Behavioral features tended to be in the 
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middle of the importance ranking. Demographic characteristics were generally less important with age 
and household size being exceptions. 
Ideally, this research could be continued using data of the same patients over time to analyze 
the new onset of diabetes in statin-using prediabetic patients specifically. The results of the analysis 
could be used to determine which features are the most important in predicting whether a high-risk 
patient using statins will develop new-onset diabetes. If these features differ from our findings of which 
factors medical decision makers are currently taking into consideration when prescribing statins, this 
could be cause for these decision makers to re-evaluate the criteria they use to make these decisions. In 
this case we would have a baseline for current practices and an analysis determining which features 
should be used in practice. 
For future research on current practices specifically, we recommend investigating different 
model types with different sets of features to try to improve model performance and including more 
health-related features. It could be impactful to see how or if comorbidities affect statin initiation in 
prediabetic patients. Oversampling methods could also be used in attempt to improve prediction 
accuracy because the model is currently under-predicting statin use.  
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5. Appendix 
 
1) Results of Chi-square multicollinearity study 
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